Mirum Pharmaceuticals, INC Form 4 insider transactions

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, reported the sale of 8,000 common shares and the exercise of 2,954 employee stock options.

Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options and sold 40,000 shares for a significant gain under a pre-arranged trading plan.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, reported a planned future sale of 10,000 shares of common stock at $58.00 per share after exercising options at $6.27.

Mirum Pharmaceuticals CEO Christopher Peetz exercised and sold 40,000 shares of common stock as part of a pre-arranged trading plan.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, reported the acquisition of common stock from restricted stock unit vesting and subsequent sales to cover tax obligations and under a pre-arranged trading plan.

William Fairey, a director at Mirum Pharmaceuticals, sold 3,203 shares of common stock at a price of $48.4204 on June 11, 2025.

A director at Mirum Pharmaceuticals, Saira Ramasastry, has reported the sale of all her directly held common stock and shares acquired through option exercise, resulting in zero direct beneficial ownership.

Mirum Pharmaceuticals Director Saira Ramasastry reported the acquisition of 5,703 shares of common stock through RSU vesting, alongside new grants of 6,268 stock options and 3,977 restricted stock units.

Mirum Pharmaceuticals, Inc. Director Patrick J. Heron filed a Form 4 detailing the acquisition of common stock through RSU conversion and the grant of new stock options and deferred stock units.

Mirum Pharmaceuticals, Inc. Director Michael G. Grey was granted 6,268 stock options and 3,977 deferred stock units on May 29, 2025, as part of his compensation.

Mirum Pharmaceuticals, Inc. Director Laura Brege reported the acquisition of 5,703 shares of common stock through RSU conversion, along with new grants of 6,268 stock options and 3,977 deferred stock units, increasing her beneficial ownership.

William Fairey, a Director at Mirum Pharmaceuticals, Inc., has acquired additional common stock, stock options, and deferred stock units as part of compensation, increasing his beneficial ownership.

Mirum Pharmaceuticals, Inc. Director Lon Cardon has reported the acquisition of common stock, stock options, and restricted stock units, alongside the disposition of previously held restricted stock units, as detailed in a recent SEC Form 4 filing.

Mirum Pharmaceuticals, Inc. Director Laurent Fischer was granted 6,268 stock options and 3,977 restricted stock units on May 29, 2025, as part of his compensation package.

Mirum Pharmaceuticals, Inc. Director Timothy P. Walbert reported the acquisition of common stock through RSU vesting and the grant of new stock options and restricted stock units.

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports selling 2,415 shares of common stock at an average price of $44.4484.

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations and those executed under a Rule 10b5-1 plan.

Peter Radovich, President and COO of Mirum Pharmaceuticals, reports the vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations.

Christopher Peetz, CEO of Mirum Pharmaceuticals, reports the acquisition and disposal of company stock, including the vesting of performance restricted stock units and sales to cover tax obligations.

Director Patrick Heron reports purchases of Mirum Pharmaceuticals stock through Frazier Life Sciences X, L.P. and Frazier Life Sciences IX, L.P.

Director Patrick J. Heron reported purchases of Mirum Pharmaceuticals (MIRM) common stock through Frazier Life Sciences X, L.P.

Director Patrick J. Heron reports purchases of Mirum Pharmaceuticals stock through Frazier Life Sciences X, L.P., and indirect ownership through Frazier Life Sciences IX, L.P.

Director Patrick Heron reported purchases of Mirum Pharmaceuticals (MIRM) common stock through Frazier Life Sciences X, L.P. and Frazier Life Sciences IX, L.P.

Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc., sold shares of common stock on March 4, 2025.

CEO Christopher Peetz exercised stock options and sold shares of Mirum Pharmaceuticals on March 3, 2025, according to a Form 4 filing with the SEC.

Peter Radovich, President and COO of Mirum Pharmaceuticals, sold 2,627 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Mirum Pharmaceuticals CEO Christopher Peetz sold 9,102 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Peter Radovich, President and COO of Mirum Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Eric Bjerkholt, CFO of Mirum Pharmaceuticals, reports the vesting and disposal of restricted stock units.